Bristol Myers Squibb’s next multiple myeloma pill iberdomide—marketed as Zenbexus—won FDA accelerated approval for patients whose disease has returned or progressed after treatment. The agency’s decision adds another oral option in a rapidly evolving myeloma setting where positioning against existing standard-of-care therapies continues to tighten. Iberdomide is part of BMS’s broader strategy to expand its multiple myeloma franchise beyond infusion therapies. The accelerated pathway signals that confirmatory evidence will be required, but it also accelerates time-to-patient access for a segment with limited durable options. For biotech investors and commercial teams, the approval matters because it potentially shifts the competitive balance toward oral regimens in relapsed disease and influences upcoming treatment algorithms as additional data mature. The FDA’s action also underscores how expedited regulatory review remains a critical lever for late-stage oncology developers seeking market share quickly.